imipenem/cilastatin

pharmaceutical drug combination

DBpedia resource is: http://dbpedia.org/resource/Imipenem/cilastatin

Abstract is: Imipenem/cilastatin, sold under the brand name Primaxin among others, is an antibiotic useful for the treatment of a number of bacterial infections. It is made from a combination of imipenem and cilastatin. Specifically it is used for pneumonia, sepsis, endocarditis, joint infections, intra-abdominal infections, and urinary tract infections. It is given by injection into a vein or muscle. Common side effects include nausea, diarrhea, and pain at the site of injection. Other side effects may include Clostridium difficile diarrhea and allergic reactions including anaphylaxis. It is unclear if use during pregnancy is safe for the baby. Imipenem is in the carbapenem family of medications and works by interfering with the bacteria's cell wall. Cilastatin blocks the activity of dehydropeptidase I which prevents the breakdown of imipenem. Imipenem/cilastatin was first sold in 1987. It is on the World Health Organization's List of Essential Medicines.

C₂₈H₄₅N₅O₁₀S₂

imipenem/cilastatin is …
instance of (P31):
type of mixture of chemical entitiesQ119892838

sublass of (P279):
combination drugQ1779868

External links are
P267ATC codeJ01DH51
P233canonical SMILESCC(C1C2CC(=C(N2C1=O)C(=O)O)SCCN=CN)O.CC1(CC1C(=O)NC(=CCCCCSCC(C(=O)O)N)C(=O)O)C.O
P231CAS Registry Number92309-29-0
P683ChEBI ID5880
P592ChEMBL IDCHEMBL296854
P661ChemSpider ID21106325
P3117DSSTox substance IDDTXSID90872430
P9635electronic Essential Medicines List medicine ID600
P646Freebase ID/m/07pf88
P234InChIInChI=1S/C16H26N2O5S.C12H17N3O4S.H2O/c1-16(2)8-10(16)13(19)18-12(15(22)23)6-4-3-5-7-24-9-11(17)14(20)21;1-6(16)9-7-4-8(20-3-2-14-5-13)10(12(18)19)15(7)11(9)17;/h6,10-11H,3-5,7-9,17H2,1-2H3,(H,18,19)(H,20,21)(H,22,23);5-7,9,16H,2-4H2,1H3,(H2,13,14)(H,18,19);1H2/b12-6-;;/t10-,11-;6-,7-,9-;/m11./s1
P235InChIKeyDAYDLKPFBFPKHL-MYZPLXEGSA-N
P2017isomeric SMILESCC1(C)C[C@@H]1C(O)=N/C(=C\CCCCSC[C@@H](N)C(=O)O)C(=O)O.C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(SCCNC=N)C[C@H]12.O
P7830LiverTox IDImipenemcilastatin
P10245MedlinePlus drug identifiera686013
P486MeSH descriptor IDD000077728
P672MeSH tree codeD02.065.589.099.124.300.500.500
D02.455.426.392.368.533.200.500
D03.633.100.300.124.300.500.500
D10.251.355.325.200.500
D26.310.356
P6366Microsoft Academic ID2781255259
P2115NDF-RT IDN0000020158
P662PubChem CID11954222
P3345RxNorm ID34482
P11089UniChem compound ID43381651
P11143WikiProjectMed IDImipenem/cilastatin

P527has part(s)cilastatinQ418201
imipenQ425152
P366has usemedicationQ12140
P8026LiverTox likelihood scoreLiverTox toxicity likelihood category DQ83284515
P3489pregnancy categoryUS pregnancy category CQ28123617
P2868subject has roleessential medicineQ35456
P12081WHO Aware ClassificationwatchQ122925721

Reverse relations

research intervention (P4844)
Q61924658A De-Escalating Strategy for Antibiotic Treatment of Pneumonia in The Medical Intensive Care Unit (0787B-092)
Q63596610Antibacterial Prophylaxis vs no Prophylaxis for Hematological Malignancies Patients Before Allo-HSCT
Q63600004DetectAB - Detecting Antibiotics
Q113898389Efficacy and Safety of Colistin Based Antibiotic Therapy
Q63338822Ertapenem Versus Meropenem/Imipenem for ESBL+ Gram-negative Infections
Q63402258Evaluation of Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults With Complicated Urinary Tract Infections
Q113932271Evaluation of the Efficacy and Safety of Intravenous Imipenem/Cilastatin/XNW4107 in Comparison With Meropenem in Hospitalized Adults With cUTI Including AP (EudraCT no. 2022-000061-40)
Q113932276Evaluation of the Efficacy and Safety of Intravenous Imipenem/Cilastatin/XNW4107 in Comparison With Recarbrio in Adults With HABP /VABP (EudraCT no. 2022-000081-18)
Q113895218Evidence Based Management of Acute Biliary Pancreatitis
Q61980590Fosfomycin Plus Imipenem for Treatment of Infective Endocarditis
Q62030827Imipenem in Critically Ill Patients
Q113914561Imipenem/Cilastatin/Relebactam (IMI/REL) in Treatment of CRE Infections
Q63571684Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia (MK-7655A-016)
Q113914265Imipenem/Cilastatin/Relebactam PK in ECMO
Q113916561Intrapulmonary Pharmacokinetics of XNW4107, Imipenem and Cilastatin in Healthy Subjects
Q113919489PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN
Q113911874Pharmacokinetics of XNW4107 in Subjects With Various Degrees of Renal Function
Q61924812Resistance Rates and Mechanisms of Resistance to Imipenem and Meropenem at UPMC
Q63582084Second-generation Sequencing Guides the Treatment of Severe Pneumonia
Q61957076Study of the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone for the Treatment of Complicated Urinary Tract Infection (cUTI) (MK-7655-003)
Q61956969Study of the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone to Treat Complicated Intra-Abdominal Infection [cIAI] (MK-7655-004)
Q63579665Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex
Q62811153Temocillin Versus a Carbapenem as Initial Intravenous Treatment for ESBL Related Urinary Tract Infections
Q63572632The Analysis of Factors Influencing the Vd of Imipenem in Septic Shock Patients
Q113913810To Evaluate the Pharmacokinetics of XNW4107 in Healthy Adult Young Females and in Healthy Adult Elderly Males and Females.

main subject (P921)
Q593338841339. Results for the Supplemental Microbiological Modified Intent-to-Treat (SmMITT) Population of the RESTORE-IMI 1 Trial of Imipenem/Cilastatin/Relebactam (IMI/REL) vs. Imipenem/Cilastatin Plus Colistin (IMI+CST) in Patients with Imipenem-Nonsuscep
Q593287841951. Nephrotoxicity Associated With Imipenem/Cilastatin/Relebactam (IMI/REL) vs. Imipenem/Cilastatin Plus Colistin (IMI+CST) in Patients With Imipenem-Nonsusceptible (NS) Bacterial Infections
Q89864905A Comparison of Treatment Outcomes Between Analysis Populations in the RESTORE-IMI 1 Phase 3 Trial of Imipenem/Cilastatin/Relebactam Versus Colistin Plus Imipenem/Cilastatin in Patients With Imipenem-Nonsusceptible Bacterial Infections
Q42677494A Multicenter Comparative Study of Meropenem and Imipenem/Cilastatin in the Treatment of Complicated Urinary Tract Infections in Hospitalized Patients
Q44398805A Retrospective Study on the Incidence of Seizures among Neurosurgical Patients Who Treated with Imipenem/Cilastatin or Meropenem
Q40072736A carbapenem antibiotic imipenem/cilastatin induces an oxidative stress-status and gonadotoxic effects in « wistar » rats
Q40694715A case of severe pneumonia in an elderly man, caused by Citrobacter freundii suspected to have a low susceptibility to imipenem/cilastatin sodium
Q68014789A clinical phase I study on intramuscular imipenem/cilastatin sodium
Q81540974A clinical study of imipenem/cilastatin in the treatment of generalized and localized infections
Q44723269A clinical study on imipenem/cilastatin sodium in the field of pediatrics
Q40779841A comparative study of ceftriaxone plus amikacin, ceftazidime plus amikacin and imipenem/cilastatin in the empiric therapy of febrile granulocytopenic cancer patients
Q40695798A comparative study of imipenem/cilastatin sodium BID vs QID in the treatment of infections associated with hematopoietic disorders
Q45286739A comparison of imipenem/cilastatin with the combination of cefuroxime and metronidazole in the treatment of intra-abdominal infections
Q24813784A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744].
Q60310408A multicenter, double-blind, randomized, comparison study of the efficacy and safety of tigecycline to imipenem/cilastatin to treat complicated intra-abdominal infections in hospitalized subjects in China
Q42935997A multicenter, randomized controlled clinical study on biapenem and imipenem/cilastatin injection in the treatment of respiratory and urinary tract infections
Q70395125A multiclinic randomized study of the comparative efficacy, safety and tolerance of imipenem/cilastatin and moxalactam
Q90924998A novel analytical method to assess the effect of imipenem/cilastatin on liver function laboratory indexes in Chinese underage inpatients: Probability distribution curve
Q40491154A novel chitosan-polyethylene oxide nanofibrous mat designed for controlled co-release of hydrocortisone and imipenem/cilastatin drugs
Q80282088A post hoc subgroup analysis of meropenem versus imipenem/cilastatin in a multicenter, double-blind, randomized study of complicated skin and skin-structure infections in patients with diabetes mellitus
Q72956657A randomized multicenter trial of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of severe intra-abdominal infections. Swedish Study Group
Q43834733A randomized, controlled clinical trial of meropenem and imipenem/cilastatin in the treatment of acute bacterial infections
Q44352883A randomized, controlled clinical trial on meropenem versus imipenem/cilastatin for the treatment of bacterial infections
Q72479622A serial application study on twice daily dose of imipenem/cilastatin in patients undergoing slow hemodialysis
Q24601509Adverse events associated with meropenem versus imipenem/cilastatin therapy in a large retrospective cohort of hospitalized infants
Q53744779Aerosolization of imipenem/cilastatin prevents pseudomonas-induced acute lung injury.
Q40605272An open, randomised, multi-centre study comparing the safety and efficacy of sitafloxacin and imipenem/cilastatin in the intravenous treatment of hospitalised patients with pneumonia
Q44621628Basic and clinical studies on imipenem/cilastatin sodium in the pediatric field
Q53993909Biapenem versus imipenem/cilastatin in the treatment of complicated intra-abdominal infections: report from a Swedish Study Group.
Q28305833Carbapenems, a new class of beta-lactam antibiotics. Discovery and development of imipenem/cilastatin
Q45111890Cefazolin plus ceftazidime versus imipenem/cilastatin monotherapy for treatment of CAPD peritonitis--a randomized controlled trial.
Q41255069Ceftriaxone versus imipenem/cilastatin as empirical monotherapy for infections in cancer patients
Q35649855Cerebrospinal fluid penetration of imipenem and cilastatin (primaxin) in children with central nervous system infections
Q42274517Cholestasis in imipenem/cilastatin treatment
Q68047623Clearance of imipenem/cilastatin in acute renal failure patients treated by continuous hemodiafiltration (CAVHD)
Q43988234Clinical and pharmacokinetic evaluation of imipenem/cilastatin sodium in children
Q34508279Clinical and pharmacokinetic study of imipenem/cilastatin in children and newborn infants
Q43553822Clinical comparative study of sulbactam/ampicillin and imipenem/cilastatin in elderly patients with community-acquired pneumonia
Q44420238Clinical efficacy of imipenem/cilastatin sodium in patients with respiratory tract infections caused by Pseudomonas aeruginosa
Q44001871Clinical efficacy of intravenous doripenem in patients with acute biliary tract infection: a multicenter, randomized, controlled trial with imipenem/cilastatin as comparator
Q44587546Clinical efficacy, safety and tolerability of intramuscular imipenem/cilastatin in the treatment of mild to moderate infections
Q46313989Clinical evaluation of imipenem/cilastatin in the therapy of severe infections in high-risk patients
Q40722073Clinical evaluation of imipenem/cilastatin sodium and fosfomycin as second-line combination chemotherapy in severe infections associated with hematologic disorders
Q40745950Clinical evaluation of imipenem/cilastatin sodium as a second line regimen in severe infections associated with hematologic disorders
Q43559973Clinical evaluation of imipenem/cilastatin sodium in gynecological infection
Q68671076Clinical evaluation of imipenem/cilastatin sodium in infectious complications of hematological malignancies. Tohkai Research Group on Infections in Hematological Disorders
Q40745955Clinical evaluation of imipenem/cilastatin sodium in the internal medicine
Q44183665Clinical evaluation of imipenem/cilastatin sodium in the pediatric field
Q70266032Clinical evaluation of the imipenem/cilastatin combination in the therapy of severe infections in patients with malignant diseases
Q33458016Clinical experience with imipenem/cilastatin: analysis of a multicenter study.
Q68756753Clinical outcome of nosocomial pneumonia following imipenem/cilastatin therapy
Q35261869Clinical pharmacology of imipenem and cilastatin in premature infants during the first week of life
Q44080894Clinical studies of efficacy of imipenem/cilastatin sodium against urinary tract infections with ureterocutaneostomy
Q40782103Clinical studies on imipenem/cilastatin sodium in perinatal use
Q67929773Clinical studies on imipenem/cilastatin sodium in the early therapy of preterm premature rupture of the membrane or threatened abortion and premature delivery
Q67929774Clinical studies on imipenem/cilastatin sodium in the field of obstetrics and gynecology
Q46953736Clinical study of imipenem/cilastatin sodium in children with severe infections
Q40782098Clinical study of imipenem/cilastatin sodium in the perinatal period
Q44939905Clinical study of intramuscular imipenem/cilastatin sodium in the field of obstetrics and gynecology
Q67869105Clinical study of intramuscular imipenem/cilastatin sodium in the field of obstetrics and gynecology
Q45281507Clinical study of the effectiveness of imipenem/cilastatin sodium as the antibiotics of first choice in the expectant management of patients with preterm premature rupture of membranes
Q54404609Clinical trial of imipenem/cilastatin in severely burned and infected patients.
Q44375965Combined effect of clarithromycin and imipenem/cilastatin against urinary biofilm infection after pyeloplasty
Q43580816Combined imipenem/cilastatin and tobramycin therapy of multiresistant Pseudomonas aeruginosa in cystic fibrosis
Q54795375Comparative clinical evaluation of imipenem/cilastatin vs. cefotaxime in treatment of severe bacterial infections.
Q68088836Comparative clinical trial of ceftazidime and imipenem/cilastatin in patients with severe nosocomial pneumonias and septicaemias
Q54345954Comparative efficacy of ciprofloxacin, azlocillin, imipenem/cilastatin and tobramycin in a model of experimental septicemia due to Pseudomonas aeruginosa in neutropenic mice.
Q68001717Comparative neurotoxicity of benzylpenicillin, imipenem/cilastatin and FCE 22101, a new injectible penem
Q89609405Comparative review of imipenem/cilastatin versus meropenem
Q40601273Comparative study of piperacillin/tazobactam versus imipenem/cilastatin in febrile neutropenia (1994-1996)
Q40670429Comparative study of the cost-/effectiveness relationship of initial therapy with imipenem/cilastatin in nosocomial pneumonia. Group study
Q45127959Comparative study of the cost-effectiveness of initial therapy with imipenem/cilastatin in secondary peritonitis
Q40660341Comparison between monotherapy with imipenem/cilastatin sodium (IPM/CS) and combinations of IPM/CS and other drugs for treating bacterial infections in patients with hematopoietic disorders
Q45580188Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation
Q36406755Comparison of efficacy of cefoperazone/sulbactam and imipenem/cilastatin for treatment of Acinetobacter bacteremia.
Q54651976Comparison of imipenem/cilastatin with the combination of aztreonam and clindamycin in the treatment of intra-abdominal infections.
Q46951637Comparison of piperacillin/tazobactam and imipenem/cilastatin, both in combination with tobramycin, administered every 6 h for treatment of nosocomial pneumonia
Q42905606Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia
Q68777079Concomitant immunosuppressive and antibiotic therapy--reduction of cyclosporine A blood levels due to treatment with imipenem/cilastatin
Q42279374Correlation between in vitro and in vivo models of proconvulsive activity with the carbapenem antibiotics, biapenem, imipenem/cilastatin and meropenem
Q43544436Cost efficacy of tazobactam/piperacillin versus imipenem/cilastatin in the treatment of intra-abdominal infection
Q44223071Cost-effectiveness of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients
Q33535030Cost-effectiveness of ceftazidime or imipenem/cilastatin versus ceftriaxone + aminoglycoside in the treatment of febrile episodes in neutropenic cancer patients in Germany
Q73713616Cost-effectiveness study of imipenem/cilastatin versus meropenem in intra-abdominal infections
Q36346133Cost-minimization analysis of imipenem/cilastatin versus meropenem in moderate to severe infections at a tertiary care hospital in Saudi Arabia
Q74619018Cost-minimization analysis of piperacillin/tazobactam versus imipenem/cilastatin for the treatment of serious infections: a Canadian hospital perspective
Q89678458Determination of Total and Unbound Meropenem, Imipenem/Cilastatin and Cefoperazone/Sulbactam in Human Plasma: Application for Therapeutic Drug Monitoring in Critically Ill Patients
Q68746318Determination of imipenem and cilastatin in serum and tissue by high-pressure liquid chromatography
Q39848938Determination of imipenem and cilastatin in serum by high-pressure liquid chromatography
Q72497007Determination of imipenem and cilastatin sodium in Primaxin by first order derivative ultraviolet spectrophotometry
Q39849271Disposition of radiolabeled imipenem and cilastatin in normal human volunteers
Q72909389Drug utilization evaluation of imipenem/cilastatin in patients with renal dysfunction
Q36093598Early use of imipenem/cilastatin and vancomycin followed by de-escalation versus conventional antimicrobials without de-escalation for patients with hospital-acquired pneumonia in a medical ICU: a randomized clinical trial
Q50046889Effect of Elevated Imipenem/Cilastatin MICs on Patient Outcomes in Gram-negative Bloodstream Infections.
Q40689555Effect of a combination treatment using imipenem/cilastatin sodium with G-CSF on infections in neutropenic patients with hematological malignancies
Q54447959Effect of imipenem/cilastatin on the colonic microflora.
Q44732972Effect of moxifloxacin versus imipenem/cilastatin treatment on the mortality of mice infected intravenously with different strains of Bacteroides fragilis and Escherichia coli
Q44103026Effectiveness of imipenem/cilastatin (Tienam, MSD) in treating complicated infections in urology
Q70264573Effects of beta-lactam antibiotics imipenem/cilastatin and cefodizime on cellular and humoral immune responses in BALB/c-mice
Q74628286Effects of fosfomycin and imipenem/cilastatin on nephrotoxicity and renal excretion of vancomycin in rats
Q73469851Effects of imipenem and cilastatin on human T-lymphocytes derived from acute leukemia patients with chemotherapy-induced leucopenia: studies of T-lymphocyte responses in the presence of acute myelogenous leukemia (AML) blast accessory cells
Q54141127Efficacy and safety of imipenem/cilastatin in the empirical treatment of septicemia.
Q39830861Efficacy and safety of imipenem/cilastatin: a review of worldwide clinical experience.
Q33642184Efficacy and safety of tigecycline monotherapy vs. imipenem/cilastatin in Chinese patients with complicated intra-abdominal infections: a randomized controlled trial
Q33456282Efficacy and tolerance of imipenem/cilastatin in the treatment of surgical infections with and without bone involvement
Q69839257Efficacy of imipenem/cilastatin in endocarditis
Q68751641Efficacy of imipenem/cilastatin in patients with severe bacterial infections
Q54273050Efficacy of sodium imipenem/cilastatin on patients of complicated urinary tract infections--following the failure of prior antimicrobial agents
Q40661480Empirical monotherapy with meropenem versus imipenem/cilastatin for febrile episodes in neutropenic patients
Q59808268Erratum for Rhee et al., "Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a β-Lactamase Inhibitor, in Combination with Imipenem and Cilastatin in Healthy Participants"
Q47392097Evaluation and financial impact of imipenem/cilastatin dosing in elderly patients based on renal function and body weight.
Q28333592Evaluation of an imipenem/cilastatin target drug program
Q50202435Evaluation of imipenem/cilastatin against nosocomial infections and multiresistant pathogens
Q68392435Evaluation of imipenem/cilastatin for treatment of infection in an elderly population
Q40766330Evaluation of imipenem/cilastatin sodium in the treatment of respiratory tract infections
Q35229009Evaluation of the appropriateness of imipenem/cilastatin prescription and dosing in a tertiary care hospital
Q81541341Evaluation of the efficacy and safety of imipenem/cilastatin in the treatment of complicated urinary tract infections
Q54108342Evaluation of the efficacy and tolerance of intravenously administered imipenem/cilastatin in the treatment of septicaemia.
Q68751643Experience with imipenem/cilastatin in the intensive care unit
Q43848037Experience with imipenem/cilastatin sodium in the field of obstetrics and gynecology
Q54206754Exposure to imipenem/cilastatin causes nephrotoxicity and even urolithiasis in Wistar rats.
Q68136446Factors predisposing to seizures in seriously ill infected patients receiving antibiotics: experience with imipenem/cilastatin
Q70481355First- and second-derivative spectrophotometric determination of imipenem and cilastatin in injections
Q41758206Formulary review of the carbapenems: comparison of imipenem/cilastatin and meropenem
Q44188273Fundamental and clinical studies of imipenem and imipenem/cilastatin sodium in the field of obstetrics and gynecology
Q40807621Fundamental and clinical studies on imipenem/cilastatin sodium in the field of obstetrics and gynecology
Q43622256Fundamental and clinical studies on imipenem/cilastatin sodium in the field of obstetrics and gynecology
Q44137033Fundamental study of imipenem/cilastatin sodium in obstetrics and gynecology
Q37883801Hospitalized patients with community-acquired pneumonia in Hong Kong: a randomized study comparing imipenem/cilastatin and ceftazidime
Q43435837Imipenem and cilastatin in acute osteomyelitis and suppurative arthritis. Therapy in infants and children
Q44238260Imipenem/Cilastatin Drug Utilization Evaluation in a Large Community Hospital
Q74064105Imipenem/cilastatin (1.5 g daily) versus meropenem (3.0 g daily) in patients with intra-abdominal infections: results of a prospective, randomized, multicentre trial
Q70125128Imipenem/cilastatin (Primaxin): evaluation in general surgical practice
Q74218096Imipenem/cilastatin as empirical treatment of severe infections in compromised patients
Q44434908Imipenem/cilastatin as initial single-agent therapy for infections in cancer patients with neutropenia.
Q40782113Imipenem/cilastatin as initial therapy for febrile neutropenic patients
Q40781913Imipenem/cilastatin as monotherapy in neutropenic patients with fever
Q69914732Imipenem/cilastatin as monotherapy in severe infections: comparison with cefotaxime in combination with metronidazole and cloxacillin. Report from a Norwegian Study Group
Q43808938Imipenem/cilastatin as monotherapy in the treatment of acute or chronic lung infections: clinical efficacy and safety.
Q68032937Imipenem/cilastatin as secondary therapy for bacterial infections
Q68751646Imipenem/cilastatin as secondary therapy for infections in cancer patients
Q69848463Imipenem/cilastatin efficacy evaluated
Q38841887Imipenem/cilastatin encapsulated polymeric nanoparticles for destroying carbapenem-resistant bacterial isolates.
Q50202098Imipenem/cilastatin for pediatric infections in hospitalized patients.
Q54791146Imipenem/cilastatin for the treatment of infections in hospitalized children.
Q81541391Imipenem/cilastatin in a group of obstetrics/gynecological surgical patients
Q44274507Imipenem/cilastatin in acute pulmonary exacerbations of cystic fibrosis
Q72198502Imipenem/cilastatin in the treatment of CAPD peritonitis
Q39830851Imipenem/cilastatin in the treatment of intraabdominal infections: a review of worldwide experience
Q63359882Imipenem/cilastatin in the treatment of obstetric and gynecologic infections
Q39830855Imipenem/cilastatin in the treatment of obstetric and gynecologic infections: a review of worldwide experience
Q54448592Imipenem/cilastatin in the treatment of osteomyelitis.
Q40816832Imipenem/cilastatin in the treatment of serious bacterial infections
Q67923210Imipenem/cilastatin in the treatment of severe hospital infections
Q51766033Imipenem/cilastatin in the treatment of severe nosocomial pneumonia.
Q40662817Imipenem/cilastatin monotherapy as salvage treatment in febrile neutropenic patients
Q77176679Imipenem/cilastatin reduces cyclosporin-induced tubular damage in kidney transplant recipients
Q37064932Imipenem/cilastatin sodium (IPM/CS) as an embolic agent for transcatheter arterial embolisation: a preliminary clinical study of gastrointestinal bleeding from neoplasms
Q72849499Imipenem/cilastatin sodium in the treatment of continuous ambulatory peritoneal dialysis-associated peritonitis
Q92071599Imipenem/cilastatin sodium/relebactam fixed combination to treat urinary infections and complicated intra-abdominal bacterial infections
Q44603924Imipenem/cilastatin therapy for serious bacterial infections.
Q54141123Imipenem/cilastatin therapy for serious infections in neonates and infants.
Q54448574Imipenem/cilastatin therapy of bacteremia.
Q40795266Imipenem/cilastatin therapy of infections in cancer patients
Q54015568Imipenem/cilastatin therapy of serious infections: a U.S. multicenter noncomparative trial.
Q68588488Imipenem/cilastatin treatment of acute infections in AIDS/ARC patients
Q28328448Imipenem/cilastatin treatment of bacterial meningitis in children
Q68788906Imipenem/cilastatin treatment of lower extremity skin and soft tissue infections in diabetics
Q69975216Imipenem/cilastatin treatment of multiresistant Pseudomonas aeruginosa lung infection in cystic fibrosis
Q40801571Imipenem/cilastatin versus amikacin plus piperacillin in the treatment of infections in neutropenic patients: a prospective, randomized multi-clinic study
Q40801578Imipenem/cilastatin versus aminoglycoside plus amoxicillin plus clindamycin in the treatment of serious postoperative infections
Q40687693Imipenem/cilastatin versus ceftazidime-amikacin in the treatment of febrile neutropenic patients
Q72576304Imipenem/cilastatin versus gentamicin/clindamycin for treatment of serious bacterial infections. Report from a Scandinavian Study Group
Q44419033Imipenem/cilastatin versus gentamicin/clindamycin: a cost effectiveness study
Q41791319Imipenem/cilastatin versus piperacillin plus amikacin as empiric therapy in the treatment of febrile episodes in neutropenic patients with haematologic malignancies
Q40505651Imipenem/cilastatin versus piperacillin/tazobactam plus amikacin for empirical therapy in febrile neutropenic patients: results of the COSTINE study
Q54447773Imipenem/cilastatin vs. gentamicin/clindamycin for the treatment of moderate to severe infections in hospitalized patients.
Q40394880Imipenem/cilastatin with or without glycopeptide as initial antibiotic therapy for recipients of autologous stem cell transplantation: results of a Spanish multicenter study.
Q70391535Imipenem/cilastatin, an alternative treatment of pseudomonas infection in cystic fibrosis
Q68751655Imipenem/cilastatin: a multicentre international study of its clinical efficacy, safety and potential as empirical therapy
Q33560379Imipenem/cilastatin: a pharmacoeconomic appraisal of its use in intra-abdominal infections
Q40675256Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections
Q44146647Imipenem/cilastatin: evolution of the sustained-release intramuscular formulation
Q54448584Imipenem/cilastatin: general experience in a community hospital.
Q39514968Imipenem/cilastatin: its use in the treatment of foot infections in the compromised host
Q68788903Imipenem/cilastatin: monotherapy of hospital infections
Q69839263Imipenem/cilastatin: pharmacokinetic profile in renal insufficiency
Q45011718Imipenem/cilastatin: rationale for a fixed combination
Q39839168Imipenem/cilastatin: the first carbapenem antibiotic.
Q67914128Impact of imipenem/cilastatin on cyclosporine metabolism and excretion
Q70963564Impact of imipenem/cilastatin therapy on faecal flora
Q54448579Impact of imipenem/cilastatin therapy on normal fecal flora.
Q92124941Impact of renal impairment and human organic anion transporter inhibition on pharmacokinetics, safety and tolerability of relebactam combined with imipenem and cilastatin
Q49172635In vitro effect of cefodizime, imipenem/cilastatin and co-trimoxazole on dexamethasone and cyclosporin A depressed phagocytosis
Q40900452In vitro effects of meropenem and imipenem/cilastatin on some functions of human natural effector cells.
Q31462845Incidence of seizures in pediatric cancer patients treated with imipenem/cilastatin
Q67978759Increased risk of central nervous system toxicity in patients treated with ciclosporin and imipenem/cilastatin
Q54415418Intramuscular imipenem/cilastatin for treatment of mild and moderately severe bacterial infections.
Q37268931Intramuscular imipenem/cilastatin in multiple-dose treatment regimens: review of the worldwide clinical experience
Q68239266Intramuscular imipenem/cilastatin in the treatment of mild and moderate infections
Q54083338Intramuscular imipenem/cilastatin treatment of upper reproductive tract infection in women: efficacy and use characteristics.
Q47195583Intrapulmonary Pharmacokinetics of Relebactam, a Novel β-lactamase Inhibitor, Dosed in Combination with Imipenem/Cilastatin in Healthy Subjects
Q49099046Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. Meropenem Serious Infection Study Group
Q44539356Laboratory and clinical studies of imipenem/cilastatin sodium in the pediatric field
Q44442591Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: A multicenter, prospective, randomized, open-label study
Q73254586Levofloxacin in the empirical treatment of patients with suspected bacteraemia/sepsis: comparison with imipenem/cilastatin in an open, randomized trial
Q53933241Meropenem (1.5 g/day) is as effective as imipenem/cilastatin (2 g/day) for the treatment of moderately severe intra-abdominal infections.
Q73417903Meropenem versus imipenem/cilastatin as empirical monotherapy for serious bacterial infections in the intensive care unit
Q54005690Meropenem versus imipenem/cilastatin in intra-abdominal infections requiring surgery. Meropenem Study Group.
Q54011895Meropenem versus imipenem/cilastatin in the treatment of hospitalized patients with skin and soft tissue infections.
Q54017571Meropenem versus imipenem/cilastatin in the treatment of intra-abdominal infections.
Q61446678Meropenem versus imipenem/cilastatin in the treatment of intraabdominal infections requiring surgery
Q42628415Meropenem versus imipenem/cilastatin in the treatment of sepsis in Chinese patients.
Q55394352Meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in ICU: an open randomised multicentre study.
Q60854937Modification of Natural Immunity in Mice by Imipenem/Cilastatin
Q60854904Modification of acquired immunity in mice by imipenem/cilastatin
Q73540713Multicenter randomized trial comparing meropenem (1.5 g daily) and imipenem/cilastatin (2 g daily) in the hospital treatment of community-acquired pneumonia
Q48659517Multicenter study of the clinical efficacy of imipenem/cilastatin for treatment of serious infections
Q44743775Multiple-dose study of imipenem/cilastatin in patients with end-stage renal disease undergoing long-term hemodialysis
Q73691103Neonatal Klebsiella pneumonia sepsis and imipenem/cilastatin
Q68753078Nephroprotective effect of imipenem/cilastatin in reducing cyclosporine toxicity
Q73136848Nephrotoxic and peroxidative potential of meropenem and imipenem/cilastatin in rat and human renal cortical slices and microsomes
Q42540781Neurological complication during imipenem/cilastatin therapy in uraemic patients
Q28370580Neurotoxicity due to imipenem/cilastatin in patients on continuous ambulatory peritoneal dialysis
Q45193539New antimicrobial agent series XXV: imipenem/cilastatin sodium
Q37106300Nonvolatile salt-free stabilizer for the quantification of polar imipenem and cilastatin in human plasma using hydrophilic interaction chromatography/quadrupole mass spectrometry with contamination sensitive off-axis electrospray
Q54447768Open trial of imipenem/cilastatin therapy for serious bacterial infections.
Q94562077Organic anion transporters also mediate the drug-drug interaction between imipenem and cilastatin
Q69854524Penetration of imipenem and cilastatin into cerebrospinal fluid of patients with bacterial meningitis
Q46122902Pharmacoeconomics of piperacillin/tazobactam and imipenem/cilastatin in the treatment of patients with intra-abdominal infections
Q68788911Pharmacokinetic and clinical evaluation of imipenem/cilastatin in children and neonates
Q44756695Pharmacokinetic and clinical evaluations of imipenem/cilastatin sodium in neonates and premature infants
Q44966538Pharmacokinetic and clinical studies of imipenem/cilastatin sodium in the pediatric field
Q68003079Pharmacokinetic and clinical studies on imipenem/cilastatin sodium in neonates and premature infants
Q70236947Pharmacokinetic and clinical studies on imipenem/cilastatin sodium in the perinatal period. A study of imipenem/cilastatin sodium in the perinatal co-research group
Q69839260Pharmacokinetic profile of imipenem/cilastatin in normal volunteers
Q72893809Pharmacokinetic profiles of intravenous imipenem/cilastatin during slow hemodialysis in critically ill patients
Q68751636Pharmacokinetic studies of imipenem/cilastatin in elderly patients
Q33448527Pharmacokinetics and clinical efficacy of imipenem/cilastatin sodium in neonates
Q44214685Pharmacokinetics and tolerance after repeated doses of imipenem/cilastatin in patients with severe renal failure
Q42019767Pharmacokinetics in healthy subjects of FCE 22101 and its acetoxymethyl ester, FCE 22891: effect of co-administration of imipenem/cilastatin on the renal metabolism of FCE 22101.
Q40445718Pharmacokinetics of Imipenem/Cilastatin Burn Intensive Care Unit Patients Undergoing High-Dose Continuous Venovenous Hemofiltration
Q46209185Pharmacokinetics of Imipenem/Cilastatin during Continuous Arteriovenous Hemofiltration
Q41884287Pharmacokinetics of imipenem and cilastatin after their simultaneous administration to the elderly
Q73261028Pharmacokinetics of imipenem and cilastatin during continuous venovenous hemodialysis in patients who are critically ill
Q39849680Pharmacokinetics of imipenem and cilastatin in patients with cystic fibrosis
Q45245144Pharmacokinetics of imipenem and cilastatin in volunteers.
Q68781836Pharmacokinetics of imipenem/cilastatin in neutropenic patients with haematological malignancies
Q44317435Pharmacokinetics of imipenem/cilastatin sodium in children with peritonitis
Q68555959Pharmacokinetics of intravenous imipenem/cilastatin during intermittent haemofiltration
Q70199366Pharmacokinetics of parenteral imipenem/cilastatin in patients on continuous ambulatory peritoneal dialysis
Q58700555Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a β-Lactamase Inhibitor, in Combination with Imipenem and Cilastatin in Healthy Participants
Q43260800Piperacillin/tazobactam versus imipenem/cilastatin for severe diabetic foot infections: a prospective, randomized clinical trial in a university hospital
Q72951194Piperacillin/tazobactam versus imipenem/cilastatin in the treatment of intra-abdominal infections
Q79803938Piperacillin/tazobactam vs imipenem/cilastatin in the treatment of nosocomial pneumonia--a double blind prospective multicentre study
Q43970361Prospective randomized comparison of imipenem/cilastatin and cefotaxime for treatment of lung, soft tissue, and renal infections
Q42558610Prospective surveillance of imipenem/cilastatin use and associated seizures using a hospital information system
Q57238114Prospective, randomised, multicentre study of meropenem versus imipenem/cilastatin as empiric monotherapy in severe nosocomial infections
Q40187323Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections
Q81541394Puerperal infections: experiences with imipenem/cilastatin
Q40694778Randomised study comparing imipenem/cilastatin to ceftriaxone plus gentamicin in cancer chemotherapy-induced neutropenic fever
Q72400725Randomized comparative trial of imipenem/cilastatin versus aminoglycoside plus amoxycillin plus clindamycin in the treatment of severe intra- and post-operative infections
Q68223453Randomized comparison of imipenem/cilastatin and ceftazidime in the empiric therapy of severe abdominal infections. A multicenter study
Q45162945Randomized comparison of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of patients with intra-abdominal infection
Q67575437Randomized multicenter clinical trial with imipenem/cilastatin versus cefotaxime/gentamicin in the treatment of patients with non-life-threatening infections. German and Austrian Imipenem/Cilastatin Study Group
Q54448558Randomized trial of imipenem/cilastatin versus gentamicin and clindamycin in mixed flora infections.
Q54431827Randomized, comparative trial of imipenem/cilastatin and moxalactam in the treatment of serious obstetric and gynecologic infections.
Q100426435Rapid detection method of carbapenemase-producing Enterobacteriaceae by MALDI-TOF MS with imipenem/cilastatin (KB) disc and zinc sulfate solution
Q44378146Rapid imipenem/cilastatin desensitization for multidrug-resistant Acinetobacter pneumonia
Q69494351Reduction of cyclosporin (CSA) nephrotoxicity by imipenem/cilastatin after kidney transplantation in rats
Q36754535Removal of imipenem and cilastatin by hemodialysis in patients with end-stage renal failure
Q43925387Renal tolerance of imipenem/cilastatin and other beta-lactam antibiotics in rats
Q28345630Results of a clinical trial of clinafloxacin versus imipenem/cilastatin for intraabdominal infections
Q44136341Results of a multicenter trial comparing imipenem/cilastatin to tobramycin/clindamycin for intra-abdominal infections
Q44625981Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections. The Intra-Abdominal Infection Study Group
Q90767936Reversible black tongue: A little known side effect of imipenem/cilastatin and evidence for novel mode of action
Q49061141Reversible encephalopathy with photoparoxysmal response during imipenem/cilastatin treatment.
Q79957074Risk factors of superinfection following imipenem/cilastatin therapy in hospitalised patients with acute exacerbations of severe chronic obstructive pulmonary disease
Q54448564Role of imipenem/cilastatin in the treatment of soft tissue infections.
Q74529484Safe use of imipenem/cilastatin in a neonatal intensive care unit
Q69839270Safety and efficacy of imipenem/cilastatin in treatment of complicated urinary tract infections
Q69888883Safety and tolerability of multiple doses of imipenem/cilastatin
Q37360448Safety of imipenem/cilastatin in neurocritical care patients
Q42198961Seizure and tremor occurring in acute leukemia patients treated with imipenem/cilastatin
Q68751649Severe gram-negative infections in neutropenic children cured by imipenem/cilastatin in combination with an aminoglycoside
Q70767148Severe neutropenia in a patient treated with imipenem/cilastatin
Q43757675Single-dose kinetics of imipenem/cilastatin during continuous arteriovenous haemofiltration in intensive care patients.
Q67296446Stability of imipenem and cilastatin sodium in total parenteral nutrient solution
Q68003090Study of imipenem/cilastatin sodium in the perinatal period
Q43717529Susceptibility of clinically isolated bacterial strains to imipenem/cilastatin sodium
Q70769424Synergic activity of imipenem/cilastatin combined with cefotiam against methicillin-resistant Staphylococcus aureus
Q87707942The Effect of Different Carbapenem Antibiotics (Ertapenem, Imipenem/Cilastatin, and Meropenem) on Serum Valproic Acid Concentrations
Q72558574The antimicrobial activity of imipenem/cilastatin and its treatment in critical ill patients with polymicrobial and mixed infection
Q45246849The cost-effectiveness of cefepime plus metronidazole versus imipenem/cilastatin in the treatment of complicated intra-abdominal infection
Q54419051The effect of imipenem/cilastatin on the aerobic faecal flora of children.
Q44896409The effects of phenytoin and phenobarbital on seizures induced by imipenem/cilastatin in rats
Q68521782The efficacy and safety of imipenem/cilastatin in the treatment of severe bacterial infections
Q39637650The efficacy results and safety profile of imipenem/cilastatin from the clinical research trials
Q93874571The penetration of imipenem/cilastatin into ascitic fluid in patients with chronic liver disease
Q68751658The safety profile of imipenem/cilastatin: worldwide clinical experience based on 3470 patients
Q44436021Therapeutic effects of imipenem/cilastatin sodium against severe infections in patients with hematopoietic disorders. Hanshin Infection Study Group
Q44113179Therapeutic efficacy of imipenem/cilastatin sodium on respiratory tract infections in lung cancer patients
Q43109993Therapeutic equivalence of generic imipenem/cilastatin for therapy of infections at Siriraj Hospital.
Q68173878Therapeutic evaluation of imipenem/cilastatin sodium for bacterial infections in patients with hematological diseases
Q39849300Therapy for lower respiratory tract infections with imipenem/cilastatin: a review of worldwide experience
Q45795512Transcatheter arterial embolization using imipenem/cilastatin sodium for tendinopathy and enthesopathy refractory to nonsurgical management
Q68239275Treatment of acute bacterial peritonitis: a trial of imipenem/cilastatin against ampicillin-metronidazole-gentamicin
Q73424503Treatment of complicated intra-abdominal infections: comparison of the tolerability and safety of intravenous/oral trovafloxacin versus intravenous imipenem/cilastatin switching to oral amoxycillin/clavulanic acid
Q81605710Treatment of diabetic foot infection: an open randomised comparison of imipenem/cilastatin and piperacillin/clindamycin combination therapy
Q68247467Treatment of intra-abdominal infections using imipenem/cilastatin
Q74594160Treatment of obstetric and gynecologic infections with meropenem: comparison with imipenem/cilastatin
Q69840250Treatment of pneumonia with imipenem/cilastatin
Q35533543Treatment of severe nosocomial pneumonia: a prospective randomised comparison of intravenous ciprofloxacin with imipenem/cilastatin
Q70868064Treatment of severe pneumonia in hospitalised patients. Results of a multicentre trial comparing i.v. ciprofloxacin with imipenem/cilastatin
Q40743949Treatment of tularemia with imipenem/cilastatin sodium
Q40734999Trimethoprim-Sulfamethoxazole plus Amikacin as First-Line Therapy and Imipenem/Cilastatin as Second Empirical Therapy in Febrile Neutropenic Patients with Hematological Disorders
Q54083343Twice daily intramuscular imipenem/cilastatin in the treatment of skin and soft tissue infections.
Q90232368Unusual Drug Fever Caused by Imipenem/Cilastatin and a Review of Literature
Q44384585Use of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients
Q91800497Use of inhaled imipenem/cilastatin in pediatric patients with cystic fibrosis: A case series
Q36338191Using imipenem and cilastatin during continuous renal replacement therapy
Q28333946Vertigo caused by intravenous imipenem/cilastatin
Q28369637Worsening of myasthenia gravis on treatment with imipenem/cilastatin
Q72818671[A multi-institutional study on the efficacy and toxicity of imipenem/cilastatin sodium in severe infections complicating hematological diseases and cancers in children. Study Group of Infectious Diseases in Pediatric Hematology/Oncology in Hokkaido
Q67929771[A randomized controlled study on imipenem/cilastatin sodium in comparison to aztreonam + lincomycin in treating severe infections in patients with malignant tumors or hematological diseases]
Q68738167[A study on the penetration of imipenem/cilastatin sodium into the female genital tissues]
Q44274999[Antibacterial activity of imipenem/cilastatin (thienam) against agents causing pyoseptic processes]
Q54782212[Bacterial and clinical studies on imipenem/cilastatin sodium in urological infection].
Q54374310[Bacteriological and clinical evaluations of imipenem/cilastatin sodium in neonates and premature infants].
Q68737454[Bone concentrations of imipenem after a dose of imipenem/cilastatin]
Q54245243[Chemotherapy with imipenem/cilastatin for severe infections accompanied by malignant hematological disorders].
Q68003074[Clinical and pharmacokinetic evaluation of imipenem/cilastatin sodium in neonates and young infants]
Q72154385[Clinical effect of the combined therapy of arbekacin and imipenem/cilastatin against methicillin-resistant Staphylococcus aureus]
Q72734699[Clinical effects of imipenem/cilastatin sodium on gynecological infections]
Q73130799[Clinical efficacy of imipenem/cilastatin sodium for respiratory infections in patients with lung cancer]
Q67929772[Clinical evaluation of imipenem/cilastatin sodium against infections in compromised children (malignancy, hematological disease, collagen disease)]
Q69430048[Clinical evaluation of imipenem/cilastatin sodium against severe infections complicated with hematological disorders and solid tumors]
Q68014795[Clinical evaluation of imipenem/cilastatin sodium against severe infections complicating hematological disorders and solid tumors]
Q70267465[Clinical evaluation of imipenem/cilastatin sodium against severe infections in patients with hematopoietic disorders]
Q68740640[Clinical evaluation of imipenem/cilastatin sodium in children]
Q54425951[Clinical evaluation of imipenem/cilastatin sodium in children].
Q67869102[Clinical evaluation of intramuscular imipenem/cilastatin sodium in surgical infections]
Q54336947[Clinical evaluation of therapy for aspiration pneumonia with imipenem/cilastatin sodium].
Q54438048[Clinical experience with imipenem/cilastatin in the treatment of severe infections in general surgery].
Q68740642[Clinical studies on imipenem/cilastatin sodium in pediatric field]
Q68003103[Clinical studies on imipenem/cilastatin sodium in the field of obstetrics and gynecology in the perinatal period]
Q68738181[Clinical studies on imipenem/cilastatin sodium in the field of obstetrics and gynecology]
Q68003097[Clinical studies on imipenem/cilastatin sodium in the perinatal period]
Q68738148[Clinical studies on the effect of imipenem/cilastatin sodium on infections in obstetrics and gynecology. Tissue concentrations and clinical effects]
Q54241799[Clinical study of imipenem/cilastatin sodium in serious infections in critical care medical center].
Q68740653[Clinical study on imipenem/cilastatin sodium in the field of pediatrics]
Q54779761[Clinical trials of imipenem/cilastatin sodium in the field of obstetrics and gynecology].
Q54302125[Combined effect of sulbactam/cefoperazone and other antibiotics against clinical isolates of multi-resistant strains. II. In vitro combined effects of sulbactam/cefoperazone with imipenem/cilastatin, cefuzonam, flomoxef, amikacin or tobramycin].
Q68740667[Concentration of imipenem/cilastatin sodium in bone marrow blood following intravenous drip infusion]
Q52885046[Contribution of imipenem/cilastatin in the treatment of peritonitis: a comparative economic analysis in the case of France]
Q70198126[Do imipenem and cilastatin interfere with the determination of serum creatinine?]
Q68901491[Effect and tolerance of daily 2 X 1 g imipenem/cilastatin in general surgery]
Q73435815[Effect of imipenem/cilastatin combined with vancomycin for MRSA infection]
Q68740668[Effect of imipenem/cilastatin sodium in thirty cases of bone and joint infection]
Q77320782[Efficacy and safety of intramuscular imipenem/cilastatin (IPM/CS) for complicated urinary tract infections]
Q68778413[Efficacy and tolerability of imipenem/cilastatin in infections at various sites]
Q54252855[Efficacy and tolerance of imipenem/cilastatin in the adjuvant treatment of surgery for peritonitis in patients over the age of 70 years]
Q68003085[Evaluation of imipenem/cilastatin sodium in neonatal infections]
Q73064044[Experience in the use of imipenem/cilastatin (thienam) in a surgical clinic]
Q70015417[Fundamental and clinical evaluation of imipenem/cilastatin sodium in the field of pediatrics]
Q68003100[Fundamental and clinical evaluation of imipenem/cilastatin sodium in the perinatal period]
Q54427166[Fundamental and clinical studies of imipenem/cilastatin sodium in the field of obstetrics and gynecology. Study group of imipenem/cilastatin sodium in the field of obstetric and gynecological infections].
Q68738163[Fundamental and clinical studies of imipenem/cilastatin sodium in the field of obstetrics and gynecology]
Q68738185[Fundamental and clinical studies of imipenem/cilastatin sodium in the field of obstetrics and gynecology]
Q93538474[Fundamental and clinical studies of imipenem/cilastatin sodium in the field of obstetrics and gynecology]
Q93538478[Fundamental and clinical studies of imipenem/cilastatin sodium in the field of obstetrics and gynecology]
Q93538483[Fundamental and clinical studies of imipenem/cilastatin sodium in the field of obstetrics and gynecology]
Q93538487[Fundamental and clinical studies of imipenem/cilastatin sodium in the field of obstetrics and gynecology]
Q54433806[Fundamental and clinical studies on imipenem/cilastatin sodium in pediatrics].
Q68738153[Fundamental and clinical studies on imipenem/cilastatin sodium in the field of obstetrics and gynecology]
Q68738196[Fundamental and clinical studies on imipenem/cilastatin sodium in the field of obstetrics and gynecology]
Q93538470[Fundamental and clinical studies on imipenem/cilastatin sodium in the field of obstetrics and gynecology]
Q93538492[Fundamental and clinical studies on imipenem/cilastatin sodium in the field of obstetrics and gynecology]
Q68740657[Fundamental and clinical studies on imipenem/cilastatin sodium in the field of pediatrics]
Q54425949[Fundamental and clinical studies on imipenem/cilastatin sodium in the pediatric field].
Q68740645[Fundamental and clinical studies with imipenem/cilastatin sodium, a new carbapenem antibiotic, in the field of pediatrics]
Q69619279[Hemostatic parameters influenced by imipenem/cilastatin]
Q69619283[Imipenem/cilastatin in surgical intensive medicine]
Q72880929[Imipenem/cilastatin sodium alone or combined with amikacin sulfate in respiratory infections]
Q77322887[Imipenem/cilastatin sodium and other beta-lactams for respiratory tract infections: clinical benefit and treatment days for cure]
Q68738172[Imipenem/cilastatin sodium in the treatment of obstetric and gynecologic infections]
Q68974050[Imipenem/cilastatin: in vitro activity, concentrations in plasma and prostatic adenoma and therapeutic results in patients with complicated urinary tract infections]
Q72832312[In vitro effects of combinations of antibiotics against highly-fosfomycin-resistant, methicillin-resistant Staphylococcus aureus. With special reference to efficacies of combinations of imipenem/cilastatin and cephems]
Q54046958[In vitro interaction of piperacillin and imipenem/cilastatin combined with aminoglycosides against Pseudomonas aeruginosa].
Q68727887[Kidney tolerance of imipenem and cilastatin]
Q67958515[Laboratory and clinical studies on imipenem/cilastatin sodium plus amikacin sulfate in patients with severe infections complicating hematological disorders]
Q53972512[Meropenem (Merrem) vs imipenem/cilastatin in hospital treatment of intra-abdominal infections. A multicenter study].
Q68738175[Outline of imipenem/cilastatin sodium]
Q68738145[Penetration of imipenem/cilastatin sodium into the tissues of the female reproductive organs]
Q73967931[Pharmacoeconomics of meropenem versus imipenem/cilastatin]
Q69531533[Pharmacokinetic and clinical evaluation of imipenem/cilastatin sodium in neonates and premature infants. A study of imipenem/cilastatin sodium by a perinatal co-research group]
Q68738191[Pharmacokinetic and clinical studies of imipenem/cilastatin sodium in the field of obstetrics and gynecology]
Q68003105[Pharmacokinetic and clinical studies of imipenem/cilastatin sodium in the perinatal period]
Q68003077[Pharmacokinetic and clinical studies with imipenem/cilastatin sodium in neonates]
Q68740664[Pharmacokinetic and clinical studies with imipenem/cilastatin sodium in the pediatric field. Pediatric Study Group for Imipenem/Cilastatin Sodium]
Q69654796[Pharmacokinetic, bacteriological and clinical studies on imipenem/cilastatin sodium in neonates]
Q54353993[Pharmacokinetic, bacteriological and clinical studies on imipenem/cilastatin sodium in neonates].
Q68003087[Pharmacokinetics and clinical evaluation of imipenem/cilastatin sodium in pediatric surgery]
Q72595269[Revaluation of current antimicrobials. Series 24: imipenem/cilastatin]
Q68740661[Studies on imipenem/cilastatin sodium in the field of pediatrics]
Q54374305[Studies on imipenem/cilastatin sodium in the perinatal period].
Q68885700[Study of the intraperitoneal penetration of imipenem/cilastatin in acute peritonitis with perforation]
Q71295124[Study of the usefulness of a kit containing imipenem/cilastatin powder with diluent for injection: accuracy of reconstitution]
Q71295118[Study of the usefulness of a kit containing imipenem/cilastatin powder with diluent for injection: convenience of use and preparation]
Q77320780[The clinical efficacy of imipenem/cilastatin sodium in orthopedic infections and drug levels in the bone tissue]
Q72188401[Thienam (imipenem/cilastatin) as an agent for empirical antibiotic therapy]
Q70321901[Treatment of bronchopulmonary infections in patients during artificial respiration with imipenem/cilastatin]
Q54149297[Treatment of respiratory tract infections with imipenem/cilastatin in critical patients with respiratory insufficiency].

Q37155World Health Organization Model List of Essential Medicineshas part(s)P527

The articles in Wikimedia projects and languages

Arabic (ar / Q13955)https://ar.wikipedia.org/wiki/اميبينيم/سيلاستاتينwikipedia
      https://en.wikipedia.org/wiki/Imipenem/cilastatinwikipedia
      https://es.wikipedia.org/wiki/Imipenem/cilastatinawikipedia
Persian (fa / Q9168)https://fa.wikipedia.org/wiki/ایمی‌پنم/سیلاستاتینwikipedia
      イミペネム・シラスタチンwikipedia
orhttps://or.wikipedia.org/wiki/ଇମିପେନେମ/ସିଲାସ୍ଟାଟିନwikipedia
      https://pt.wikipedia.org/wiki/Imipenem/cilastatinawikipedia
      https://ro.wikipedia.org/wiki/Imipenem/cilastatinwikipedia
Serbo-Croatian (sh / Q9301)https://sh.wikipedia.org/wiki/Imipenem/cilastatinwikipedia
      https://sr.wikipedia.org/wiki/Imipenem/cilastatinwikipedia
      https://vi.wikipedia.org/wiki/Imipenem/cilastatinwikipedia
      https://zh.wikipedia.org/wiki/亚胺培南/西司他丁wikipedia

Search more.